Tagged with S

USA The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) approved no less than 55 new drugs in 2023, a number surpassing that of 2022 by almost 50 percent. While 28 rare disease treatments and five novel gene therapies got the green light, the agency also…

Portugal Pfizer holds a prominent position in Portugal’s pharmaceutical landscape, especially in the hospital business and for COVID-19-related products, with the emphasis now on sustainable growth post-COVID. Paulo Teixeira, a 26-year pharma industry veteran, lays out his strategy for the affiliate and highlights some of the key challenges in Portugal’s healthcare…

India Vikrant Shrotiya outlines how Novo Nordisk’s phenomenal recent global performance in obesity and diabetes has played out in India and the relevance of India to the global group. He also examines some of the key affordability and access challenges in the Indian market and how the company is engaging in…

India The Bombay Chamber of Commerce, established in 1836, played a key role in India’s industrial and infrastructural development during British rule and has since evolved into a professional organization with influential members, contributing significantly to the growth of major international companies like Tata and Reliance. Director General Sandeep Khosla highlights…

USA Cardiff Advisory’s David H. Crean outlines the positive atmosphere and sentiment observed at JPM 2024, the annual healthcare financing conference held near San Francisco’s Union Square. Dr. Crean picks up some of the key trends to emerge from the conference around sustainability, deal flow, venture funding, and AI, and provides…

Legal Handbook Preclinical and clinical trial requirements in India. Prepared in association with Nishith Desai & Associates, a leading law firm in India, this is an extract from The Pharma Legal Handbook: India, available to purchase here for GBP 119.   1. Are clinical trials required to be conducted locally as a condition…

Portugal Ana Fereira highlights how the twin factors of people and time have shaped her leadership approach, how she is navigating the challenging generic medicines landscape in Portugal, and why STADA has chosen to put a strategic focus on biosimilars and sustainability.   I see STADA becoming one of the top…

India Drawing on over 30 years of industry experience across a wide range of global markets, Pierre Perez today adopts an open-minded approach to leading Servier’s operations in India. Having fostered a collaborative and communicative working environment at the affiliate, Servier India has achieved double-digit annual growth, expanded its portfolio, and…

Portugal Mario Martins lays out IQVIA Portugal’s holistic approach to the healthcare sector, covering clinical trials, therapeutic studies, and technology solutions such as compliance CRM and quality control for manufacturing plants. He also foregrounds the importance of both local adaptation and global collaboration in capitalising on the unique challenges and opportunities…

Portugal Health Cluster Portugal is currently spearheading a EUR 90 million EU post-COVID Recovery and Resilience Plan (RRP) project in Portugal focused on smart health, secondary use of data, and clinical trials. Executive Director Joaquim Cunha highlights the ways in which COVID acted as a catalyst for healthcare transformation more broadly,…

Portugal Sérgio Alves describes the personal and professional factors that drove his return to Portugal, where he draws on enriching experiences gained from working in various European markets. He also discusses how AstraZeneca’s COVID-19 vaccine served as a jumping-off point for more wide-ranging discussions with governmental stakeholders, and the affiliate’s positive…

Portugal Portugal boasts a well-developed universal healthcare system and saw healthcare spending increase by 6.2 percent annually between 2016 and 2021, according to the OECD. However, the representatives of innovative medicines manufacturers embedded in the country are keen to point out that access to the latest drugs remains a big issue…